The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
 
Katherine Cynthia Fuh
Honoraria - aravive; AstraZeneca; GlaxoSmithKline; Immunogen; Mersana
Consulting or Advisory Role - Aravive
Research Funding - Genentech/Roche (Inst); Merck
Patents, Royalties, Other Intellectual Property - AVB-S6-500
 
Zaza Tsitsishvili
No Relationships to Disclose
 
Thomas J. Reid
No Relationships to Disclose
 
Ugo De Giorgi
No Relationships to Disclose
 
Lauren Hand
No Relationships to Disclose
 
Rebecca Bowen
No Relationships to Disclose
 
Devin Miller
No Relationships to Disclose
 
Christof Vulsteke
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Atheneum; Bayer; Bristol-Myers Squibb/Pfizer; GlaxoSmithKline; ipsen; Janssen; LEO Pharma; MSD; Pfizer; Roche/Genentech
Research Funding - LEO Pharma (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Roche
 
Sudarshan K. Sharma
No Relationships to Disclose
 
Anita M. Chudecka-Głaz
No Relationships to Disclose
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron; Zentalis
Research Funding - 2X Oncology (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Regeneron (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)
 
Lauriane Eberst
No Relationships to Disclose
 
Robert Neff
Consulting or Advisory Role - AADi; AstraZeneca
 
Peter C Lim
No Relationships to Disclose
 
David A. Iglesias
Research Funding - Genmab/Seagen (Inst); GlaxoSmithKline (Inst); Novocure (Inst)
 
Tilley Jenkins Vogel
Consulting or Advisory Role - GlaxoSmithKline
 
Tashanna K. N. Myers
Consulting or Advisory Role - Immunogen; Immunogen
 
Antonio González-Martín
No Relationships to Disclose
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Clovis Oncology; Genmab; Hedera Dx; Immunogen; Kartos Therapeutics; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK